Kun-Chun Chiang

Kun-Chun Chiang

Auto-generated profile, based on publicly available information

Kun-Chun Chiang

General Surgery Department, Chang Gung Memorial Hospital, Keelung, Taiwan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2017 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
KTKe‐Hung Tsui
Ke‐Hung Tsui
KCKun‐Chun Chiang
Kun‐Chun Chiang
YLYu‐Hsiang Lin
Yu‐Hsiang Lin
KCKang‐Shuo Chang
Kang‐Shuo Chang
TFTsui‐Hsia Feng
Tsui‐Hsia Feng
HJHorng-Heng Juang
Horng-Heng Juang
Although widely deemed as a tumor suppressor gene, the role of B‐cell translocation gene 2 (BTG2) in bladder cancer is still inconclusive. We investigated the role and regulatory mechanism of BTG2 in bladder cancer. BTG2 expression in human bladder tissues was determined by RT‐qPCR and immunoblotting assays. Expressions of BTG2 and PTEN in bladder carcinoma cells were determined by immunoblotting, RT‐qPCR, or reporter assays. The 3H‐thymidine incorporation assay, flow cytometry, and the xenograft animal model were used to determine the cell growth. BTG2 expression was lower in human bladder cancer tissues than normal bladder tissues. Highly differentiated bladder cancer cells, RT4, expressed higher BTG2 than the less‐differentiated bladder cancer cells, HT1376 and T24. Overexpression of BTG2 in T24 cells inhibited cell growth in vitro and in vivo. Camptothecin and doxorubicin treatments in RT‐4 cells or transient overexpression of p53 into p53‐mutant HT1376 cells induced p53 and BTG2 expression. Further reporter assays with site‐mutation of p53 response element from GGGAAAGTCC to GGAGTCC within BTG2 promoter area showed that p53‐induced BTG2 gene expression was dependent on the p53 response element. Ectopic PTEN overexpression in T24 cells blocked the Akt signal pathway which attenuated cell growth via upregualtion of BTG2 gene expression, while reverse effect was found in PTEN‐knockdown RT‐4 cells. PTEN activity inhibitor (VO‐OHpic) treatment decreased BTG2 expression in RT‐4 and PTEN‐overexpressed T24 cells. Our results suggested that BTG2 functioned as a bladder cancer tumor suppressor gene, and was induced by p53 and PTEN. Modulation of BTG2 expression seems a promising way to treat human bladder cancer.

1 November 2014 in Cancer Letters
Verified
Journal Article
Closed access
KCKun-Chun Chiang
Kun-Chun Chiang
CYChun-Nan Yeh
Chun-Nan Yeh
JHJun-Te Hsu
Jun-Te Hsu
YJYi-Yin Jan
Yi-Yin Jan
LCLi-Wei Chen
Li-Wei Chen
HJHorng-Heng Juang
Horng-Heng Juang

1 December 2015 in Cancer Letters
Verified
Journal Article
Closed access
KCKun-Chun Chiang
Kun-Chun Chiang
SKSheng-Fong Kuo
Sheng-Fong Kuo
CCChien-Hung Chen
Chien-Hung Chen
SNSohching Ng
Sohching Ng
SLShu-Fu Lin
Shu-Fu Lin
JPJong-Hwei Pang
Jong-Hwei Pang

1 February 2019 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
KCKun-Chun Chiang
Kun-Chun Chiang
SHSheng-Teng Huang
Sheng-Teng Huang
RWRen-Chin Wu
Ren-Chin Wu
SHShih-Chiang Huang
Shih-Chiang Huang
TYTa-Sen Yeh
Ta-Sen Yeh
JPJong-Hwei Pang
Jong-Hwei Pang
Objective: Cholangiocarcinoma (CCA) is a devastating disease. Interferon α-inducible protein 27 (IFI27), originally known to involve in innate immunity, is later found to intervene in cell proliferation, leading to inventive studies regarding the role of IFI27 in cancer treatment. We aimed to investigate the role of IFI27 in CCA. Materials and methods: Cell proliferation, migration, and invasion assays, Western blot, gene transfection and knockdown, immunofluorescent and immunohistochemical stains, and xenograft animal model were applied. Results: IFI27 knockdown in CCA cells induced cell cycle arrest in S phase, resulting in lower cell proliferative rate in vitro and in vivo. IFI27 knockdown attenuated CCA cell migration and invasion through inhibition of epithelial–mesenchymal transition, which was supported by increased E-cadherin and decreased N-cadherin and fibronectin. Filamentous actin level was also reduced. IFI27 knockdown further repressed expression and secretion of vascular endothelial growth factor (VEGF-A), a strong stimulator of angiogenesis, through downregulation of c-jun and c-fos, which was supported in vitro by the finding that human vascular endothelial cells grew more slowly in conditioned medium of IFI27 knockdown on CCA cells and in vivo by the lower erythropoietin concentration found in the xenografted tumors derived from IFI27 knockdown on CCA cells. In addition, anti-VEGF-A antibody treatment was able to repress CCA cell growth. To the contrary, IFI27 overexpression could increase CCA cell proliferation, migration, and invasion. Clinically, higher IFI27 expression was linked to inferior overall survival of CCA patients. Conclusion: Our data strongly suggest that IFI27 could be deemed as a potential target for CCA treatment.

1 March 2017 in International Journal of Surgery
Verified
Journal Article
Closed access
CYChun-Nan Yeh
Chun-Nan Yeh
Shang Yu WangShang Yu Wang
Shang Yu Wang
CTChun-Yi Tsai
Chun-Yi Tsai
YCYen-Yang Chen
Yen-Yang Chen
CLChing-Ting Liu
Ching-Ting Liu
TYTa-Sen Yeh
Ta-Sen Yeh
For selected patients with metastatic gastrointestinal stromal tumor (GIST) who have received first-line imatinib (IM) and are undergoing cytoreductive surgery, response to IM at time of surgery correlates with resection completeness as well as favorable progression-free survival (PFS) and overall survival (OS). However, surgical impact in GIST patients receiving second-line sunitinib (SU) is still not well clarified. Between 2001 and 2014, 86 of 311 metastatic GIST patients received SU. Among them, 69 patients eventually experienced progression. Twenty-six patients who experienced local progression (LP) and underwent surgeries were investigated. Each tumor was assessed for genetic alterations before and after surgery. Twenty-six GIST patients receiving SU who experienced LP underwent surgery after a median of 6.2 months of SU use. Nineteen patients (73.1%) had undergone prior surgery on IM. The complication rate was 15.3%, and no additional operation was required for GIST patients receiving SU and experiencing LP who underwent surgery. The median PFS and OS times after surgery and start of SU were 5.2 and 18.9 months, respectively, and 16.4 and 26.0 months, respectively (median follow-up of 15.2 months). GIST patients receiving SU with LP (N = 26) may gain a significant PFS and OS benefit with surgery when compared with those not undergoing surgery (N = 43) (p = 0.003 and p = 0.02, respectively). Secondary exon 17 mutation occurred commonly and might explain SU resistance (8/23; 34.8%). Surgery is feasible in highly selected patients with metastatic GIST who are receiving SU and experiencing LP. Those patients may also have significantly prolonged PFS and OS after surgery. Secondary exon 17 mutation might explain SU resistance.

1 January 2016 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
KCKun-Chun Chiang
Kun-Chun Chiang
CSChi-Chin Sun
Chi-Chin Sun
MCMing-Huang Chen
Ming-Huang Chen
Chi-Ying F. HuangChi-Ying F. Huang
Chi-Ying F. Huang
JHJun-Te Hsu
Jun-Te Hsu
JPJong-Hwei Pang
Jong-Hwei Pang